SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced that the number of shares and voting rights has increased by 2,883,725 following the completion of the directed issue of new shares resolved by the Board of Directors on March 2, 2026.
On March 2, 2026, SynAct announced that the Board of Directors had, by virtue of the authorization from the Annual General Meeting on May 27, 2025, resolved on a directed issue of 2,883,725 new shares. Consequently, as of March 31, 2026, the total number of registered shares in SynAct amounts to 56,213,968 and the total number of votes in SynAct amounts to 56,213,968.